circulating tumor DNA
Tethis, Weill Cornell Partner for CTC, cfDNA Analysis of Blood Samples in Early Breast Cancer
Weill Cornell researchers will use Tethis' platform to prepare blood samples for cell-free DNA and circulating tumor cell analysis.
Foresight Diagnostics Adds $33M to Series B Financing Round
The company has now raised $73.8 million in the round and plans to use the new funding to advance development of its Clarity minimal residual disease assay.
Quest's Haystack Oncology, U of Montreal to Study Liquid Biopsy MRD Test in Colorectal Cancer
The partners will use Haystack's MRD test to assess treatment response and detect early relapse in colorectal cancer patients with liver metastasis.
Gene Solutions, National Cancer Society of Malaysia Forge Multi-Cancer Early Detection Partnership
The partnership will focus on awareness, community outreach, accessibility, and data sharing.
Roche Sues Foresight Diagnostics, Stanford Over Cancer Detection Technology
Roche has accused Foresight's founders of misusing technology Roche acquired in 2015 in funding their own startup.
Jun 5, 2024
Jan 12, 2024